EUVIMEDEUVIMED entdecken
Multizentrische Studie

The Fate of Normocalcemic Hyperparathyroidism: Insights from a 3-Year Multicenter Follow-Up

Mazhar Müslüm Tuna, Berçem Ayçiçek, İsmail Engin, Asena Gökçay Canpolat, Yusuf Kır, Ceren Tufan, Ekin Yiğit Köroğlu, Kenan Sakar, Ahmet Görgel, Dılek Kılınç Candemır, Yudum Yaprak Usda Konak, Mustafa Aydemır und 9 weitere

Hormone and Metabolic Research · 01.05.2026 · 58 (05) · 163-170

DOI: 10.1055/a-2812-1864 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Hormone and Metabolic Research, erschienen am 01.05.2026. Verfasst von Mazhar Müslüm Tuna und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, University of Health Sciences, Umraniye Training and Research Hospital, Istanbul, Türkiye. Hauptthemen laut MEDLINE: Calcium, Hypercalcemia, Hyperparathyroidism, Primary, Hyperparathyroidism. Die Arbeit nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Normocalcemic primary hyperparathyroidism is thought to be an early form of hypercalcemic primary hyperparathyroidism. However, some studies have shown progression to hypercalcemia, hypercalciuria or kidney stones, bone loss and fractures in a proportion of patients over time, whereas other studies have not observed such outcomes. The aim of this study was to investigate the clinicopathological features and natural history of the disease in a large patient population and to provide clinicians with strong evidence-based recommendations. This is a nationwide, multicenter, observational, retrospective cohort study. Tertiary healthcare endocrinology departments were the setting for this study. Data from different regions of Turkey, including 527 patients, were included in this study. A total of 123 patients were not eligible for inclusion, and the remaining 404 patients were included in the final analysis. All laboratory assessments, dual-energy X-ray absorptiometry and renal ultrasound were performed locally at each center at baseline and several times during follow-up. The mean age was 54.63±11.41 years. As expected, there was a female predominance of 362 (89.4%). A total of 376 patients were followed up for 1 year and 252 patients for 3 years. Forty-seven out of 404 patients (11.6%) developed hypercalcemia within 3 years. Twenty-eight patients became hypercalcemic within the 1st year, and 19 patients became hypercalcemic within 3 years. Among the 47 patients, only four patients had a calcium level above 11 mg/dL during the follow-up. Nephrolithiasis was detected in 50 patients (12.6%). There was no significant difference in calcium, parathyroid hormone, 25-hydroxyvitamin D, or urinary calcium levels or the presence of nephrolithiasis. Bone mineral density assessments revealed that only 90 patients (28.5%) had normal bone mineral density. A total of 135 (42.7%) patients had osteopenia, and 91 (28.8%) patients had osteoporosis at least one site at presentation. This study revealed that patients with normocalcemic primary hyperparathyroidism have significant adverse skeletal outcomes, a slight increase in kidney stones. Only a small proportion of patients develop hypercalcemia, and the risk of developing significant hypercalcemia that would alter the patient’s treatment management is much lower.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CalciumHypercalcemiaHyperparathyroidism, PrimaryHyperparathyroidismHumansFemaleMaleMiddle AgedFollow-Up StudiesAdultRetrospective StudiesAged

Substanzen

Calcium

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, University of Health Sciences, Umraniye Training and Research Hospital, Istanbul, Türkiye.
  • Department of Endocrinology and Metabolism, Istinye University, Faculty of Medicine, Istanbul, Türkiye.
  • Department of Endocrinology and Metabolism, Ankara University, Faculty of Medicine, Ankara, Türkiye.
  • Department of Endocrinology and Metabolism, University of Health Sciences, Gulhane Training and Research Hospital, Ankara, Türkiye.
  • Department of Endocrinology and Metabolism, Canakkale Onsekiz Mart University, Faculty of Medicine, Canakkale, Türkiye.
  • Department of Endocrinology and Metabolism, Ankara City Hospital, Ankara, Türkiye.

Zitieren

APA

Tuna, M. M., Ayçiçek, B., Engin, İ., Gökçay Canpolat, A., Kır, Y., Tufan, C., Köroğlu, E. Y., Sakar, K., Görgel, A., Kılınç Candemır, D., Konak, Y. Y. U., Aydemır, M., Şahın, M., Gülçelık, N. E., Karakiliç, E., Çakır, B., Akbaba, G., Baldane, S., Kilinç, F., …, & Sari, R. (2026). The Fate of Normocalcemic Hyperparathyroidism: Insights from a 3-Year Multicenter Follow-Up. Hormone and Metabolic Research, 58(05), 163-170. https://doi.org/10.1055/a-2812-1864

Vancouver

Tuna MM, Ayçiçek B, Engin İ, Gökçay Canpolat A, Kır Y, Tufan C, et al. The Fate of Normocalcemic Hyperparathyroidism: Insights from a 3-Year Multicenter Follow-Up. Hormone and Metabolic Research. 2026;58(05):163-170. doi:10.1055/a-2812-1864

BibTeX
@article{Tuna2026,
  author = {Tuna, Mazhar Müslüm and Ayçiçek, Berçem and Engin, İsmail and Gökçay Canpolat, Asena and Kır, Yusuf and Tufan, Ceren and Köroğlu, Ekin Yiğit and Sakar, Kenan and Görgel, Ahmet and Kılınç Candemır, Dılek and Konak, Yudum Yaprak Usda and Aydemır, Mustafa and Şahın, Mustafa and Gülçelık, Neşe Ersöz and Karakiliç, Ersen and Çakır, Bekır and Akbaba, Gülhan and Baldane, Süleyman and Kilinç, Faruk and Bılgıner, Cüneyt and Sari, Ramazan},
  title = {The Fate of Normocalcemic Hyperparathyroidism: Insights from a 3-Year Multicenter Follow-Up},
  journal = {Hormone and Metabolic Research},
  year = {2026},
  volume = {58},
  number = {05},
  pages = {163--170},
  doi = {10.1055/a-2812-1864}
}
Kostenlos starten →